E. González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
E. González has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Berta Laquente
Medical Oncology Department, Institut Català d’Oncologia (ICO), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), 08908 Barcelona, Spain
1 shared publication - E. Dotor
Corporació Sanitària Parc Taulí, Barcelona, Spain
1 shared publication - E. Martínez
Hospital Universitario Marqués de Valdecilla, Santander, Spain
1 shared publication - Jaime Feliu
Oncology Department, Hospital La Paz Institute for Health Research—IdiPAZ, Hospital Universitario La Paz, 28029 Madrid, Spain
1 shared publication - Joan Maurel
Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain
1 shared publication - Jose Luis Manzano
Department of Oncology, Institut Català d’Oncologia (ICO)-Badalona, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 28 November 2016
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 18 (12) , 1172-1178
SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)
Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.
- 28 November 2016
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 18 (12) , 1172-1178
Open AccessSEOM Clinical Guideline for the treatment of pancreatic cancer (2016)
Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.